Daptomycin for enterococcal bacteraemia: the case for higher doses

This Lancet Infectious Diseases review addresses an awkward gap. Daptomycin is widely used for serious enterococcal bloodstream infection and endocarditis, yet it has no FDA or EMA approval for these, no randomised trials, and inconsistent breakpoints: CLSI sets a susceptible dose-dependent category for E faecium at 8–12 mg/kg daily, while EUCAST sets no breakpoint at all.

The authors argue that this mismatch leads to underdosing. Observational data link 10–12 mg/kg daily with lower mortality in vancomycin-resistant E faecium, though target attainment depends heavily on the isolate's MIC, which routine methods measure poorly. CK elevation rises modestly with dose, with marked rises mainly at the highest doses.

Their proposed framework: at least 8 mg/kg daily for E faecium, 10–12 mg/kg in vancomycin-resistant disease, MIC-informed dosing, beta-lactam combination in endocarditis, and weekly CK checks. This is expert opinion built on observational evidence, but it matches how many ID teams already dose.

• Avoid the 6 mg/kg daily dose for serious E faecium infection; consider at least 8 mg/kg.
• Consider 10–12 mg/kg daily for vancomycin-resistant E faecium bacteraemia.
• Consider adding a beta-lactam such as ampicillin or ceftaroline in enterococcal endocarditis treated with daptomycin.
• Check CK weekly, and pause statins where possible during high-dose therapy.
• Ask the laboratory for a daptomycin MIC on serious isolates.

Why it matters

Standard-dose daptomycin may be failing patients with resistant enterococcal infection without anyone noticing.

Don't overread it

The dosing framework is expert opinion drawn from observational data; no randomised trial supports it.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.